Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer

BACKGROUND: CDK4/6 inhibitors combined with endocrine therapy are standard first- or second-line treatment for patients with HR-positive and HER2-negative advanced breast cancer, however, there is currently no optimal recommendation for therapeutic strategies after progression on CDK4/6i. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jinmei, Wu, Xuexue, Zhang, Huiqiang, Wang, Xiaobo, Yuan, Yang, Zhang, Shaohua, Jiang, Zefei, Wang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661714/
https://www.ncbi.nlm.nih.gov/pubmed/36375386
http://dx.doi.org/10.1016/j.breast.2022.10.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661714/
https://www.ncbi.nlm.nih.gov/pubmed/36375386
http://dx.doi.org/10.1016/j.breast.2022.10.018

Ejemplares similares